External Beam Radiation Therapy (EBRT)
Internal Targeted Radiotherapeutics
With internal radiation therapy, a radiation source is put inside the body via injection, infusion, inhalation or ingestion. Brachytherapy involves low- or high-dose temporary or permanent radioactive implants placed in or near the tumor while systemic therapy involves liquid radiation that travels in the blood to tissues, seeking out the tumor.
Both approaches can be very effective in treating cancer as alpha or beta radiation is delivered locally with a high level of accuracy while minimizing the risk of side effects due to the targeted and precise delivery of radiation.
Further, they require very short treatment times (1-5 days) with radiation kept in place between a few minutes to a lifetime.
Radionuclide-based therapies contain either beta, alpha or gamma energy emitters. In some cases, a single radionuclide can act as a mixed emitter of more than one type of energy. Within these classifications, radionuclides have a variety of tissue ranges, half-lives, and chemistries, each creating the opportunity to tailor a therapy’s properties to the unmet needs of certain patients or cancer types.
Some of the shortcomings of existing radiotherapeutics include the path length of certain emitters extending too far into healthy tissue, insignificant retention of the drug at the site of administration, a lack of affordability or convenience in administration, and drug carriers that are not biodegradable or biocompatible.
Our radiotherapeutic platform leverages the versatile radionuclide, Rhenium, which has a 17-hour (Rhenium-188) to 90-hour (Rhenium-186) and emits both beta and gamma energy, leading to combined therapeutic and image monitoring benefits.
We have developed innovative formulas using BMEDA-chelation, nanotechnology and microtechnology to encapsulate Rhenium isotopes and facilitate non-toxic release in the body.